# US 2020/0392164 A1 · Boronate ester compounds and pharmaceutical compositions thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392164 A1
- Document ID: US20200392164A1
- Status: Published application
- Kind: A1
- Application number: 17/009,199
- Filed: 2020-09-01
- Published: 2020-12-17
- Earliest claimed: 2008-06-17
- Assignees: Millennium Pharmaceuticals, Inc.
- Applicants: Millennium Pharmaceuticals, Inc.
- Inventors: Eric L. Elliott; Abu J. Ferdous; Michael J. Kaufman; Sonja A. Komar-Lay; Debra L. Mazaik; Quentin J. Mccubbin; Phuong M. Nguyen; Vaithianathan Palaniappan; Raymond D. Skwierczynski; Nobel T. Truong; Csanad M. Varga; Peter N. Zawaneh
- Web page: https://patentgrep.com/patent/US20200392164A1

## CPC

- C07F 5/04: Esters of boric acids
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/69: Boron compounds
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 233/83: of an acyclic saturated carbon skeleton
- C07F 5/025: {Boronic and borinic acid compounds}
- C07K 5/06139: {with the first amino acid being heterocyclic}
- C07K 5/06191: {containing heteroatoms different from O, S, or N}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

## Claims

### Claim 1

A process for generating a compound of Formula (II)
or a pharmaceutically acceptable salt thereof, wherein
A is 0, 1, or 2;
P is Rc—C(O)—; Rc is RD; RD is substituted or unsubstituted mono- or bicyclic ring system selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, naphthyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinoxalinyl, and dihydrobenzoxazinyl;
Ra is hydrogen, C1-6 aliphatic, C1-6 fluoroaliphatic, —(CH2)m—CH2—RB, —(CH2)m—CH2—NHC(═NR4)NH—Y, —(CH2)m—CH2—CON(R4)2, —(CH2)m—CH2—N(R4)CON(R4)2, —(CH2)m—CH(R6)N(R4)2, —(CH2)m—CH(R5a)—OR5b, or —(CH2)m—CH(R5)—SR5;
Ra1 is hydrogen, C1-6 aliphatic, C1-6 fluoroaliphatic, —(CH2)m—CH2—RB, —(CH2)m—CH2—NHC(═NR4)NH—Y, —(CH2)m—CH2—CON(R4)2, —(CH2)m—CH2—N(R4)CON(R4)2, —(CH2)m—CH(R6)N(R4)2, —(CH2)m—CH(R5a)—OR5b, or —(CH2)m—CH(R5)—SR5;
each Ra2 independently is hydrogen, C1-6 aliphatic, C1-6 fluoroaliphatic, —(CH2)m—CH2—RB, —(CH2)m—CH2—NHC(═NR4)NH—Y, —(CH2)m—CH2—CON(R4)2, —(CH2)m—CH2—N(R4)CON(R4)2, —(CH2)m—CH(R6)N(R4)2, —(CH2)m—CH(R5a)—OR1b, or —(CH2)m—CH(R5)—SR5;
each RB independently is a substituted or unsubstituted mono- or bicyclic ring system;
each R4 independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R4 on the same nitrogen atom, taken together with the nitrogen atom, form a substituted or unsubstituted 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms independently selected from N, O, and S;
each R5 independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each R5a independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each R5b independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each R6 independently is a substituted or unsubstituted aliphatic, aryl, or heteroaryl group;
Y is hydrogen, —CN, or —NO2;
m is 0, 1, or 2;
each of Rb1 and Rb2 independently is hydrogen, —CO2H, —OH, or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each of Rb3 and Rb4 independently is hydrogen, —CO2H, or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
or Rb2 and Rb4 are each independently hydrogen, and Rb1 and Rb3, taken together with the carbon atoms to which they are attached, form an unsubstituted or substituted fused 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S, wherein said ring may be optionally fused to an unsubstituted or substituted 4- to 8-membered non-aromatic ring, or 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S;
or Rb2 and Rb4 are absent, and Rb1 and Rb3, taken together with the carbon atoms to which they are attached, form an unsubstituted or substituted fused 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S, wherein said ring may be optionally fused to an unsubstituted or substituted 4- to 8-membered non-aromatic ring, or 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S; and
n is 0 or 1;
the process comprising:
(1) coupling a compound of Formula (i) with a compound of Formula (ii) to form a compound of Formula (iii)
wherein X− is a counter anion; and PG is hydrogen or a protecting group;
(2) deprotecting the compound of Formula (iii) to form a compound of Formula (iiia)
(3) coupling the compound of Formula (iiia) with a compound, P-LG, to form a compound of Formula (iv)
wherein LG is a leaving group;
(4) deprotecting the compound of Formula (iv) to form the compound of Formula (v)
and
(5) reacting the compound of Formula (v) with an alpha hydroxy carboxylic acid or a beta hydroxy carboxylic acid to form a compound of Formula (II).

### Claim 2 (depends on 1)

The process of claim 1, wherein the reaction of step (1) or step (3) or both is conducted in the presence of a peptide coupling reagent.

### Claim 3 (depends on 2)

The process of claim 2, wherein the peptide coupling reagent is selected from the group consisting of a carbodiimide reagent, phosphonium reagent, and uronium reagent.

### Claim 4 (depends on 3)

The process of claim 3, wherein the peptide coupling reagent is selected from one or more of the group consisting of dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), and O-(1H-benzotriazol-1-yl)-N,N,N′N′-tetramethyluronium tetrafluoroborate (TBTU).

### Claim 5 (depends on 1)

The process of claim 1, further comprising converting the carboxylic acid moiety of compound (ii) to an activated ester or acid halide prior to the reaction of step (1).

### Claim 6 (depends on 5)

The process of claim 5, wherein said activated ester or acid halide is an O—(N-hydroxysuccinnimide) ester.

### Claim 7 (depends on 1)

The process of claim 1, wherein the reaction of step (3) is conducted in the presence of a solvent.

### Claim 8 (depends on 7)

The process of claim 7, wherein the solvent is tetrahydrofuran.

### Claim 9 (depends on 1)

The process of claim 1, wherein the reaction of step (4) is conducted in the presence of an aqueous mineral acid.

### Claim 10 (depends on 9)

The process of claim 9, wherein the mineral acid is hydrochloric acid.

### Claim 11 (depends on 1)

The process of claim 1, wherein the reaction of step (4) is conducted in the presence of an organic boronic acid acceptor.

### Claim 12 (depends on 11)

The process of claim 11, wherein the organic boronic acid acceptor is i-BuB(OH)2.

### Claim 13 (depends on 1)

The process of claim 1, wherein the reaction of step (5) is conducted in the presence of a solvent selected from the group consisting of ethyl acetate, methyl isobutyl ketone, acetone, acetonitrile, 2-methyltetrahydrofuran, anisole, isopropyl acetate, dimethoxyethane, tetrahydrofuran, dioxane, dichloromethane, toluene, heptane, methyl-cyclohexane, tert-butylmethyl ether, and any combination thereof.

### Claim 14 (depends on 1)

The process of claim 1, wherein the reaction of step (5) is conducted in the presence of a catalyst, wherein the catalyst is an organic amine base.

### Claim 15 (depends on 14)

The process of claim 14, wherein the catalyst is selected from the group consisting of triethylamine, triethylenediamine, pyridine, collidine, 2,6-lutidine, 4-dimethylaminopyridine, di-tertbutylpyridine, N-methylmorpholine, N-methylpiperidine, tetramethylguanidine, diazabicyclo[5.4.0]undec-7-ene (DBU), 1,4-diazabicyclo[2.2.2]octane, 1,5-diazabicycle[4.3.0]non-5-ene, N,N′diisopropylethylamine, or any combination thereof.

### Claim 16 (depends on 1)

The process of claim 1, wherein step (5) further comprises cooling the solution.

### Claim 17 (depends on 16)

The process of claim 16, wherein the cooling comprises cooling the solution uncontrolled until the internal temperature is about 25° C.

### Claim 18 (depends on 1)

The process of claim 1, wherein the reaction of step (5) is conducted in the presence of a co-solvent.

### Claim 19 (depends on 18)

The process of claim 18, wherein the co-solvent is selected from the group consisting of heptane, methylcyclohexane, toluene, tert-butylmethyl ether, ethyl acetate, or any combination thereof.

### Claim 20 (depends on 1)

The process of claim 1, further comprising
(6) isolating the compound of Formula (II) as a crystalline solid.

### Claim 21 (depends on 1)

The process of claim 1, wherein PG is a protecting group selected from the group consisting of an acyl protecting group and a urethane protecting group.

### Claim 22 (depends on 21)

The process of claim 21, wherein PG is a protecting group selected from the group consisting of formyl, acetyl, succinyl, methoxysuccinyl, tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and fluorenylmethoxycarbonyl (Fmoc).

### Claim 23 (depends on 1)

The process of claim 1, wherein LG is —Cl.

### Claim 24 (depends on 1)

The process of claim 1, wherein X− is CF3CO2.

### Claim 25 (depends on 1)

The process of claim 1, wherein RD is 2,5-dichlorophenyl.

### Claim 26 (depends on 1)

The process of claim 1, wherein
A is 0;
Ra is C1-6 aliphatic;
Ra1 is hydrogen, C1-6 aliphatic, —(CH2)m—CH2—RB, or —(CH2)m—CH(R5a)—OR5b;
each of Rb1 and Rb2 independently is hydrogen, —CO2H, —OH, or a substituted or unsubstituted aliphatic;
each of Rb3 and Rb4 independently is hydrogen, C1-6 aliphatic, or —(CH2)pCO2H; and
p is 0 or 1.

### Claim 27 (depends on 1)

The process of claim 1, wherein
A is 0;
RD is 2,5-dichlorophenyl;
Ra is isobutyl;
Ra1 is hydrogen;
each Rb1 and Rb2 independently is hydrogen;
each Rb3 and R4 independently is —(CH2)p—CO2H; p is 0 or 1; and n is 0 or 1.

### Claim 28 (depends on 1)

The process of claim 1, wherein the alpha hydroxy carboxylic acid or a beta hydroxy carboxylic acid is citric acid.

### Claim 29 (depends on 1)

The process of claim 1, wherein the compound of Formula (II) is 4-(R,S)-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid.

### Claim 30 (depends on 1)

The process of claim 1, wherein the compound of Formula (II) is 2,2′-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid.

### Claim 31

A process for generating a compound of Formula (II)
or a pharmaceutically acceptable salt thereof, wherein
A is 0, 1, or 2;
P is Rc—C(O)—; Rc is RD; RD is substituted or unsubstituted mono- or bicyclic ring system selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, naphthyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinoxalinyl, and dihydrobenzoxazinyl;
Ra is hydrogen, C1-6 aliphatic, C1-6 fluoroaliphatic, —(CH2)m—CH2—RB, —(CH2)m—CH2—NHC(═NR4)NH—Y, —(CH2)m—CH2—CON(R4)2, —(CH2)m—CH2—N(R4)CON(R4)2, —(CH2)m—CH(R6)N(R4)2, —(CH2)m—CH(R5a)—OR5b, or —(CH2)m—CH(R5)—SR5;
Ra1 is hydrogen, C1-6 aliphatic, C1-6 fluoroaliphatic, —(CH2)m—CH2—RB, —(CH2)m—CH2—NHC(═NR4)NH—Y, —(CH2)m—CH2—CON(R4)2, —(CH2)m—CH2—N(R4)CON(R4)2, —(CH2)m—CH(R6)N(R4)2, —(CH2)m—CH(R5a)—OR5b, or —(CH2)m—CH(R5)—SR5;
each Ra2 independently is hydrogen, C1-6 aliphatic, C1-6 fluoroaliphatic, —(CH2)m—CH2—RB, —(CH2)m—CH2—NHC(═NR4)NH—Y, —(CH2)m—CH2—CON(R4)2, —(CH2)m—CH2—N(R4)CON(R4)2, —(CH2)m—CH(R6)N(R4)2, —(CH2)m—CH(R5a)—OR5b, or —(CH2)m—CH(R5)—SR5;
each RB independently is a substituted or unsubstituted mono- or bicyclic ring system;
each R4 independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R4 on the same nitrogen atom, taken together with the nitrogen atom, form a substituted or unsubstituted 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms independently selected from N, O, and S;
each R5 independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each R5a independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each R5b independently is hydrogen or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each R6 independently is a substituted or unsubstituted aliphatic, aryl, or heteroaryl group;
Y is hydrogen, —CN, or —NO2;
m is 0, 1, or 2;
each of Rb1 and Rb2 independently is hydrogen, —CO2H, —OH, or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each of Rb3 and Rb4 independently is hydrogen, —CO2H, or a substituted or unsubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
or Rb2 and Rb4 are each independently hydrogen, and Rb1 and Rb3, taken together with the carbon atoms to which they are attached, form an unsubstituted or substituted fused 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S, wherein said ring may be optionally fused to an unsubstituted or substituted 4- to 8-membered non-aromatic ring, or 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S;
or Rb2 and Rb4 are absent, and Rb1 and Rb3, taken together with the carbon atoms to which they are attached, form an unsubstituted or substituted fused 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S, wherein said ring may be optionally fused to an unsubstituted or substituted 4- to 8-membered non-aromatic ring, or 5- to 6-membered aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S; and
n is 0 or 1;
the process comprising:
(1a) coupling a compound of Formula (vi) with a compound, P-LG, to form a compound of Formula (vii)
wherein PG is hydrogen or a protecting group; and LG is a leaving group;
(2a) deprotecting the compound of Formula (vii) to form a compound of Formula (viia)
(3a) coupling the compound of Formula (viia) with a compound of Formula (i) to form a compound of Formula (iv)
wherein X− is a counter anion;
(4) deprotecting the compound of Formula (iv) to form a compound of Formula (v)
and
(5) reacting the compound of Formula (v) with an alpha hydroxy carboxylic acid or a beta hydroxy carboxylic acid to form a compound of Formula (II).
